IP Library › Granted Patent US 12,404,500
Granted Patent B2
US 12,404,500 · App. 17/311,464 · Granted Sep 2, 2025

Homing endonuclease variants

Inventors: Jordan Jarjour (Seattle, WA); Kyle Havens (Seattle, WA); Constantine Chrysostomou (Fairfax, VA)
Assignee: NOVO NORDISK A/S
C12N9/22C07K2319/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,500
App. No.
17/311,464
Granted
Sep 2, 2025
Kind
B2
Abstract

The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.

Claims (120)

1. An I-OnuI homing endonuclease (HE) variant comprising at least 97% sequence identity to a reference I-OnuI comprising any one of SEQ ID NOs: 1-8 and 15, further comprising at least four amino acid substitutions relative to the reference I-OnuI HE that increase the thermostability of the I-OnuI HE variant compared to the reference I-OnuI HE, and wherein the at least four of the amino acid substitutions consist of:

(i) amino acid substitutions at the following amino acid positions: 14, 19, 168, 208, and 246, in reference to SEQ ID NO: 1;

(ii) three of more amino acid substitutions at an amino acid position selected from the group consisting of: 14, 19, 116, 156, 168, 176, 208, 231, 246, 261, 263, 277, and 300, in reference to SEQ ID NO: 1; and one or more amino acid substitutions at an amino acid position selected from the group consisting of: 31, 33, 52, 97, 124, 147, 153, 209, 264, and 268, in reference to SEQ ID NO: 1;

(iii) five or more amino acid substitutions at an amino acid position selected from the group consisting of: 14, 19, 116, 156, 168, 176, 208, 231, 246, 261, 263, 277, and 300, in reference to SEQ ID NO: 1; and/or

(iv) five or more amino acid substitutions at an amino acid position selected from the group consisting of: 14, 19, 116, 156, 168, 176, 208, 231, 246, 261, 263, 277, and 300, in reference to SEQ ID NO: 1; and one or more amino acid substitutions at an amino acid position selected from the group consisting of: 31, 33, 52, 97, 124, 147, 153, 209, 264, and 268, in reference to SEQ ID NO:1.

2. The I-OnuI HE variant of claim 1 , wherein the I-OnuI HE variant has a TM 50 of:

(a) at least 10° C. higher than the TM 50 of the reference I-OnuI HE;

(b) at least 15° C. higher than the TM 50 of the reference I-OnuI HE;

(c) at least 20° C. higher than the TM 50 of the reference I-OnuI HE; or

(d) at least 25° C. higher than the TM 50 of the reference I-OnuI HE.

3. The I-OnuI HE variant of claim 1 , wherein the I-OnuI HE variant targets a site in a gene selected from the group consisting of: HBA, HBB, HBG1, HBG2, BCL11A, PCSK9, TCRA, TCRB, B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, CIITA, AHR, PD-1, CTLA4, TIGIT, TGFβR2, LAG-3, TIM-3, BTLA, IL4R, IL6R, CXCR1, CXCR2, IL10R, IL13Rα2, TRAILR1, RCAS1R, and FAS.

4. The I-OnuI HE variant of claim 1 , wherein:

(a) the amino acid at position 14 is selected from the group consisting of: T, V, S, N, M, K, F, and D;

(b) the amino acid at position 19 is selected from the group consisting of: C, D, I, L, S, T, and V;

(c) the amino acid at position 116 is selected from the group consisting of: F, D, A, L, and I;

(d) the amino acid at position 168 is selected from the group consisting of: G, H, Y, I, V, P, L, and S;

(e) the amino acid at position 208 is selected from the group consisting of: N, V, Y, and E;

(f) the amino acid at position 246 is selected from the group consisting of: H, I, D, R, S, T, V, Y, and K; and/or

(g) the amino acid at position 263 is selected from the group consisting of: H, F, P, T, V, and R.

5. The I-OnuI HE variant of claim 1 , wherein:

(a) the amino acid at position 14 is selected from the group consisting of: T and V;

(b) the amino acid at position 19 is selected from the group consisting of: T and V;

(c) the amino acid at position 116 is selected from the group consisting of: L and I;

(d) the amino acid at position 168 is selected from the group consisting of: G, L, and S;

(e) the amino acid at position 208 is E;

(f) the amino acid at position 246 is K; and/or

(g) the amino acid at position 263 is selected from the group consisting of: H and R.

6. The I-OnuI HE variant of claim 1 , wherein:

(a) the amino acid at position 156 is selected from the group consisting of: N, Q, R, T, V, I, and E;

(b) the amino acid at position 176 is selected from the group consisting of: P, N, and A;

(c) the amino acid at position 231 is selected from the group consisting of: D, K, V, and G;

(d) the amino acid at position 261 is selected from the group consisting of: M, D, G, I, L, S, T, and A;

(e) the amino acid at position 277 is selected from the group consisting of: A, D, G, Q, V, and K; and/or

(f) the amino acid at position 300 is selected from the group consisting of: S, V, D, C, and R.

7. The I-OnuI HE variant of claim 1 , wherein:

(a) the amino acid at position 156 is selected from the group consisting of: R, I, and E;

(b) the amino acid at position 176 is A;

(c) the amino acid at position 231 is selected from the group consisting of: K and G;

(d) the amino acid at position 261 is selected from the group consisting of: M and A;

(e) the amino acid at position 277 is K; and/or

(f) the amino acid at position 300 is R.

8. The I-OnuI HE variant of claim 1 , wherein:

(a) the amino acid at position 31 is selected from the group consisting of: D, H, I, R, K, S, T, and Y;

(b) the amino acid at position 33 is selected from the group consisting of: D, G, H, I, K, S, T, and Y;

(c) the amino acid at position 52 is selected from the group consisting of: Q, R, T, Y, N, E, and M;

(d) the amino acid at position 97 is selected from the group consisting of: F, N, and H;

(e) the amino acid at position 124 is selected from the group consisting of: E, N, R, and T;

(f) the amino acid at position 147 is selected from the group consisting of: E, I, N, R, and T;

(g) the amino acid at position 153 is selected from the group consisting of: D, H, K, T, Y, S, V, and N;

(h) the amino acid at position 209 is selected from the group consisting of: E, M, N, Q, and R;

(i) the amino acid at position 264 is selected from the group consisting of: A, D, G, K, Q, R, and V; and/or

(j) the amino acid at position 268 is selected from the group consisting of: A, E, G, H, N, V, and Y.

9. The I-OnuI HE variant of claim 1 , wherein:

(a) the amino acid at position 31 is K;

(b) the amino acid at position 33 is K;

(c) the amino acid at position 52 is M;

(d) the amino acid at position 97 is F;

(e) the amino acid at position 124 is N;

(f) the amino acid at position 147 is I;

(g) the amino acid at position 153 is selected from the group consisting of: D, V, and N;

(h) the amino acid at position 209 is R;

(i) the amino acid at position 264 is K; and/or

(j) the amino acid at position 268 is N.

10. The I-OnuI HE variant of claim 1 , wherein the at least four amino acid substitutions is five or more amino acid substitutions.

11. The I-OnuI HE variant of claim 1 , wherein the amino acid at position 108 is selected from the group consisting of: K and M.

12. The I-OnuI HE variant of claim 1 , wherein the amino acid at position 108 is selected from the group consisting of: E, N, Q, R, T, and V.

13. An I-OnuI homing endonuclease (HE) variant comprising at least 97% sequence identity to a reference I-OnuI HE comprising any one of SEQ ID NOs: 1-8 and 15, further comprising at least four amino acid substitutions relative to the reference I-OnuI HE, that increase the thermostability of the I-OnuI HE variant compared to the reference I-OnuI HE, and wherein the at least four of the amino acid substitutions are selected from amino acid substitutions at the following amino acid positions: 14, 19, 31, 33, 52, 97, 116, 124, 147, 153, 156, 168, 176, 208, 209, 231, 246, 261, 263, 264, 268, 277, and 300, in reference to SEQ ID NO: 1; and wherein:

(a) the amino acid at position 14 is selected from the group consisting of T, V, S, N, M, K, F, and D;

(b) the amino acid at position 19 is selected from the group consisting of C, D, I, L, S, T, and V;

(c) the amino acid at position 31 is selected from the group consisting of: D, H, I, R, K, S, T, and Y;

(d) the amino acid at position 33 is selected from the group consisting of: D, G, H, I, K, S, T, and Y;

(e) the amino acid at position 52 is selected from the group consisting of: Q, R, T, Y, N, E, and M;

(f) the amino acid at position 97 is selected from the group consisting of: F, N, and H;

(g) the amino acid at position 116 is selected from the group consisting of: F, D, A, L, and I;

(h) the amino acid at position 124 is selected from the group consisting of: E, N, R, and T;

(i) the amino acid at position 147 is selected from the group consisting of: E, I, N, R, and T;

(j) the amino acid at position 153 is selected from the group consisting of: D, H, K, T, Y, S, V, and N;

(k) the amino acid at position 156 is selected from the group consisting of: N, Q, R, T, V, I, and E;

(l) the amino acid at position 168 is selected from the group consisting of: G, H, Y, I, V, P, L, and S;

(m) the amino acid at position 176 is selected from the group consisting of: P, N, and A;

(n) the amino acid at position 208 is selected from the group consisting of: N, V, Y, and E;

(o) the amino acid at position 209 is selected from the group consisting of E, M, N, Q, and R;

(p) the amino acid at position 231 is selected from the group consisting of: D, K, V, and G;

(q) the amino acid at position 246 is selected from the group consisting of: H, I, D, R, S, T, V, Y, and K;

(r) the amino acid at position 261 is selected from the group consisting of: M, D, G, I, L, S, T, and A;

(s) the amino acid at position 263 is selected from the group consisting of: H F P T V and R;

(t) the amino acid at position 264 is selected from the group consisting of: A D, G, K, Q, R, and V;

(u) the amino acid at position 268 is selected from the group consisting of: A E, G, H, N, V, and Y;

(v) the amino acid at position 277 is selected from the group consisting of: A D, G, Q, V, and K; and/or

(w) the amino acid at position 300 is selected from the group consisting of: S, V, D, C, and R.

14. The I-OnuI HE variant of claim 13 , wherein:

(a) the amino acid at position 14 is selected from the group consisting of: T and V;

(b) the amino acid at position 19 is selected from the group consisting of: T and V;

(c) the amino acid at position 31 is K;

(d) the amino acid at position 33 is K;

(e) the amino acid at position 52 is M;

(f) the amino acid at position 97 is F;

(g) the amino acid at position 116 is selected from the group consisting of: L and I;

(h) the amino acid at position 124 is N;

(i) the amino acid at position 147 is I;

(i) the amino acid at position 153 is selected from the group consisting of: D, V, and N;

(k) the amino acid at position 156 is selected from the group consisting of: I, R, and E;

(l) the amino acid at position 168 is selected from the group consisting of: G, L, and S;

(m) the amino acid at position 176 is A;

(n) the amino acid at position 208 is E;

(o) the amino acid at position 209 is R;

(p) the amino acid at position 231 is selected from the group consisting of: K and G;

(q) the amino acid at position 246 is K;

(r) the amino acid at position 261 is selected from the group consisting of: M and A;

(s) the amino acid at position 263 is selected from the group consisting of: H and R;

(t) the amino acid at position 264 is K;

(u) the amino acid at position 268 is N;

(v) the amino acid at position 277 is K; and/or

(w) the amino acid at position 300 is R.

15. The I-OnuI HE variant of claim 13 , wherein the I-OnuI HE variant comprises five or more amino acid substitutions.

16. The I-OnuI HE variant of claim 13 , wherein the at least four of the amino acid substitutions are selected from amino acid substitutions at the following amino acid positions: 14, 19, 31, 116, 153, 156, 168, 176, 208, 246, 261, 263, and 300.

17. The I-OnuI HE variant of claim 13 , wherein the at least four of the amino acid substitutions are selected from amino acid substitutions at the following amino acid positions: 14, 153, 156, 168, 176, 246, 261, 263, and 300.

18. The I-OnuI HE variant of claim 17 , wherein the amino acid at selected position 14 is T, the amino acid at selected position 153 is V, the amino acid at selected position 156 is R, the amino acid at selected position 168 is G, the amino acid at selected position 176 is A, the amino acid at selected position 246 is I, the amino acid at selected position 261 is M, the amino acid at selected position 263 is H, and the amino acid at selected position 300 is R.

19. The I-OnuI HE variant of claim 13 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

20. The I-OnuI HE variant of claim 13 comprising an amino acid sequence set forth in SEQ ID NO: 18.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2024
From: 2SEVENTY BIO, INC.
To: NOVO NORDISK A/S
Reel/Frame 068553/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: BLUEBIRD BIO, INC.
To: 2SEVENTY BIO, INC.
Reel/Frame 057683/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2021
From: JARJOUR, JORDAN; HAVENS, KYLE; CHRYSOSTOMOU, CONSTANTINE
To: BLUEBIRD BIO, INC.
Reel/Frame 056739/0824 →
Continuity (2)
Provisional Application 62777476 · Dec 10, 2018
Related Publication 20220119784A1 · Apr 21, 2022
References Cited (170)
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4873192A · Kunkel · 1989 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 5804413A · DeLuca · 1998 [cited by applicant]
US 5837532A · Preston et al. · 1998 [cited by applicant]
US 5846782A · Wickham et al. · 1998 [cited by applicant]
US 5994136A · Naldini et al. · 1999 [cited by applicant]
US 6013516A · Verma et al. · 2000 [cited by applicant]
US 6649595B2 · Clackson et al. · 2003 [cited by applicant]
US 6682907B1 · Charneau et al. · 2004 [cited by applicant]
US 6692736B2 · Yu et al. · 2004 [cited by applicant]
US 8614092B2 · Zhang et al. · 2013 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8784799B2 · Samulski et al. · 2014 [cited by applicant]
US 8809058B2 · Ferrari et al. · 2014 [cited by applicant]
US 8889641B2 · Asokan et al. · 2014 [cited by applicant]
US 9012224B2 · Bowles et al. · 2015 [cited by applicant]
US 9017967B2 · Bonas et al. · 2015 [cited by applicant]
US 9169492B2 · Monahan et al. · 2015 [cited by applicant]
US 9169494B2 · Hewitt et al. · 2015 [cited by applicant]
US 9506120B2 · Doyon et al. · 2016 [cited by applicant]
US 11345754B2 · Hu et al. · 2022 [cited by applicant]
US 11779654B2 · Jarjour · 2023 [cited by examiner]
US 20110256607A1 · Hausner et al. · 2011 [cited by applicant]
US 20130337454A1 · Duchateau et al. · 2013 [cited by applicant]
US 20140148361A1 · Stoddard et al. · 2014 [cited by applicant]
US 20150266973A1 · Jarjour et al. · 2015 [cited by applicant]
US 20160102323A1 · Jarjour et al. · 2016 [cited by applicant]
US 20160130569A1 · Jarjour et al. · 2016 [cited by applicant]
US 20170298329A1 · Takeuchi et al. · 2017 [cited by applicant]
US 20210040165A1 · Mann et al. · 2021 [cited by applicant]
CN 101679959A · 2010 [cited by applicant]
CN 106749666A · 2017 [cited by applicant]
CN 106939049A · 2017 [cited by applicant]
EA 201492222A1 · 2015 [cited by applicant]
EP 2215223B1 · 2010 [cited by applicant]
IN 201617011596 · 2021 [cited by applicant]
JP 2010539929A · 2010 [cited by applicant]
JP 2016520308A · 2016 [cited by applicant]
WO 9102788A1 · 1991 [cited by applicant]
WO 9604394A1 · 1996 [cited by applicant]
WO 9815637A1 · 1998 [cited by applicant]
WO 9906583A1 · 1999 [cited by applicant]
WO 2006010834A1 · 2006 [cited by applicant]
WO 2007049095A1 · 2007 [cited by applicant]
WO 2011156430A2 · 2011 [cited by applicant]
WO 2012068380A2 · 2012 [cited by applicant]
WO 2012118717A2 · 2012 [cited by applicant]
WO 2013126794A1 · 2013 [cited by applicant]
WO 201414744A1 · 2014 [cited by applicant]
WO 2014184741A1 · 2014 [cited by applicant]
WO 2014184744A1 · 2014 [cited by applicant]
WO 2014191525A1 · 2014 [cited by applicant]
WO 2014191527A1 · 2014 [cited by applicant]
WO 2015017214A1 · 2015 [cited by applicant]
WO 2017156484A1 · 2017 [cited by applicant]
WO 2017177137A1 · 2017 [cited by applicant]
WO 2018022619A1 · 2018 [cited by applicant]
WO 2018035141A1 · 2018 [cited by applicant]
WO 2018035423A1 · 2018 [cited by applicant]
WO 2018039333A1 · 2018 [cited by applicant]
WO 2018049226A1 · 2018 [cited by applicant]
WO 2018071565A1 · 2018 [cited by applicant]
WO 2018075541A1 · 2018 [cited by applicant]
WO 2018218194A1 · 2018 [cited by applicant]
WO 2020123375A1 · 2018 [cited by applicant]
WO WO2020072059A1 · 2020 [cited by examiner]
Sethuraman, J., et al. “Genes within genes: multiple LAGLIDADG homing endonucleases target the ribosomal protein S3 gene encoded within an rnl group I intron of Ophiostoma and related taxa.” Molecular biology and evolut… [cited by examiner]
Takeuchi, Ryo, et al. “Tapping natural reservoirs of homing endonucleases for targeted gene modification.” Proceedings of the National Academy of Sciences 108.32 (2011): 13077-13082. (Year: 2011). [cited by examiner]
Kay et al., “A Bacterial Effector Acts as a Plant Transcription Factor and Induces a Cell Size Regulator,” Science, vol. 318, No. 5850, pp. 648-651 (Oct. 26, 2007). [cited by applicant]
Kay, J.E., “Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans somerases,” Biochem J., vol. 314 (Pt 2), pp. 361-385 (1996). [cited by applicant]
Kim et al., “Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain,” Proceedings of the National Academy of Sciences, vol. 93, No. 3, pp. 1156-1160 (1996). [cited by applicant]
Kozak, M., “An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs,” Nucleic Acids Research, vol. 15, No. 20, pp. 8125-8148 (1987). [cited by applicant]
Kozak, M., “Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes,” Cell, vol. 44, No. 2, pp. 283-292 (1986). [cited by applicant]
Kunkel, et al., “Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection,” Methods in Enzymology, vol. 154, pp. 367-382 (1987). [cited by applicant]
Kunkel, T.A., “Rapid and efficient site-specific mutagenesis without phenotypic selection,” Proc. Natl. Acad. Sci. USA, vol. 82, No. 2, pp. 488-492 (1985). [cited by applicant]
Kutner et al., “Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors,” Nature Protocols, vol. 4, No. 4, pp. 495-505 (2009). [cited by applicant]
Kutner et al., “Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography,” BMC Biotechnology, vol. 9, No. 10, pp. 1-7 (2009). [cited by applicant]
Lai et al., “Long-Term Evaluation of AAV-Mediated sFIt-1 Gene Therapy for Ocular Neovascularization in Mice and Monkeys,” Molecular Therapy, vol. 12, No. 4, pp. 659-668 (2005). [cited by applicant]
Le Gal La Salle et al., “An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain,” Science, vol. 259, pp. 988-990 (1993). [cited by applicant]
Levrero et al., “Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo,” Gene, vol. 101, pp. 195-202 (1991). [cited by applicant]
Liu et al., “Design of polydactyl zinc-finger proteins for unique addressing within complex genomes, ” Proceedings of the National Academy of Sciences USA, vol. 94, No. 11, pp. 5525-5530 (1997). [cited by applicant]
Liu et al., “HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression,” Genes & Development, vol. 9, pp. 1766-1780 (1995). [cited by applicant]
Liu et al., “Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver,” Gene Therapy, vol. 10, No. 2, pp. 180-187 (2003). [cited by applicant]
Maratea et al., “Deletion and fusion analysis of the phage phi X174 lysis gene E,” Gene, vol. 40, No. 1, pp. 39-46 (1985). [cited by applicant]
McMurrough et al., “Control of catalytic efficiency by a coevolving network of catalytic and noncatalytic residues,” PNAS, pp. E2376-E2383 (2014). [cited by applicant]
Murphy et al., “Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein,” Proc. Natl. Acad. Sci. U S A., vol. 83, No. 21, p… [cited by applicant]
Nakayama et al., “Structure of a Hyperthermophilic Archael Homing Endonuclease, I-Tsp061I: Contribution of Cross-domain Polar Networks to Thermostability,” Journal of Molecular Biology, vol. 365, pp. 362-378 (2007). [cited by applicant]
Naldini et al., “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector,” Proc. Natl. Acad. Sci. USA, vol. 93, No. 21, pp. 11382-11388 … [cited by applicant]
Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector,” Science, vol. 272, No. 5259, pp. 263-267 (1996). [cited by applicant]
Naldini, L., “Lentiviruses as gene transfer agents for delivery to non-dividing cells,” Current Opinion in Biotechnology, vol. 9, pp. 457-463 (1998). [cited by applicant]
Pâques et al., “Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy,” Current Gene Therapy, vol. 7, pp. 49-66 (2007). [cited by applicant]
Patel et al., “Impact of chimeric immune receptor extracellular protein domains on T cell function,” Gene Therapy, vol. 6, No. 3, pp. 412-419 (1999). [cited by applicant]
Platten et al., “Tryptophan Catabolismin Cancer: Beyond IDO and Tryptophan Depletion,” Cancer Research, vol. 72, No. 21, pp. 5435-5440 (2012). [cited by applicant]
Pomerantz et al., “Analysis of homeodomain function by structure-based design of a transcription factor,” Proc. Natl. Acad. Sci. USA, vol. 92, No. 21, pp. 9752-9756 (1995). [cited by applicant]
Pomerantz et al., “Structure-Based Design of Transcription Factors,” Science, vol. 267, pp. 93-96 (1995). [cited by applicant]
Ragot et al., “Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice,” Nature, vol. 361, pp. 647-650 (1993). [cited by applicant]
Reich et al., “Efficient Trans-Splicing in the Retina Expands the Utility of Adeno-Associated Virus as a Vector for Gene Therapy,” Human Gene Therapy, vol. 14, No. 1, pp. 37-44 (2003). [cited by applicant]
Rosenfeld et al., “Adenovirus-Mediated Transfer of a Recombinant alpha1-Antitrypsin Gene to the Lung Epithelium in Vivo,” Science, vol. 252, pp. 431-434 (1991). [cited by applicant]
Rosenfeld et al., “In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium,” Cell, vol. 68, pp. 143-155 (1992). [cited by applicant]
Ryan et al., “Virus-encoded proteinases of the picornavirus super-group,” Journal of General Virology, vol. 78 (Pt 4), pp. 699-723 (1997). [cited by applicant]
Sather et al., “Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template,” Sci. Transl Med., vol. 7, No. 307, pp. 1-14 (2015). [cited by applicant]
Standaert et al., “Molecular cloning and overexpression of the human FK506-binding protein FKBP,” Nature, vol. 346, No. 6285, pp. 671-674 (1990). [cited by applicant]
Sterman et al., “Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma,” Human Gene Thera… [cited by applicant]
Stoddard et al., “Homing Endonucleases: From Microbial Genetic Invaders to Reagents for Targeted DNA Modification,” Structure, vol. 19, pp. 7-15 (Jan. 12, 2011). [cited by applicant]
Stoddard, “Homing endonuclease structure and function,” Quarterly Reviews of Biophysics, vol. 38, No. 1, pp. 49-95 (2005). [cited by applicant]
Szymczak et al., “Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector,” Nature Biotechnology, vol. 22, No. 5, pp. 589-594 (2004). [cited by applicant]
Takeuchi et al., “Engineering of customized meganucleases via in vitro compartmentalization and in cellulo optimization,” Methods Mol. Biol., vol. 1239, pp. 105-132 (2015). [cited by applicant]
Takeuchi et al., “Tapping natural reservoirs of homing endonucleases for targeted gene modification,” Proceedings of the National Academy of Sciences, National Academy of Sciences, vol. 108, No. 32, pp. 13077-13082 (201… [cited by applicant]
Yan et al., “Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy,” PNAS, vol. 97, No. 12, pp. 6716-6721 (2000). [cited by applicant]
Zennou et al., “HIV-1 Genome Nuclear Import is Mediated by a Central DNA Flap,” Cell, vol. 101, No. 2, pp. 173-185 (2000). [cited by applicant]
Zhong et al., “Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication,” Molecular Therapy, vol. 18, No. 2, pp. 413-420 (2… [cited by applicant]
Zufferey et al., “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,” Nat. Biotechnol., vol. 15, No. 9, pp. 871-875 (1997). [cited by applicant]
Zufferey et al., “Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors,” Journal of Virology, vol. 73, No. 4, pp. 2886-2892 (1999). [cited by applicant]
Challita et al., “Multiple Modifications in cis Elements of the Long Terminal Repeat of Retroviral Vectors Lead to Increased Expression and Decreased DNA Methylation in Embryonic Carcinoma Cells,” Journal of Virology, v… [cited by applicant]
Ashworth et al., “Computational redesign of endonuclease DNA binding and cleavage specificity,” Nature, vol. 441, No. 7093, pp. 656-659 (Jun. 1, 2006). [cited by applicant]
Balazs et al., “Liposomes for Use in Gene Delivery,” Journal of Drug Delivery, vol. 2011, pp. 1-12 (2011). [cited by applicant]
Baxter et al., “Engineering domain fusion chimeras from I-Onul family LAGLIDADG homing endonucleases, ” Nucleic Acids Research, vol. 40, No. 16, pp. 7985-8000 (2012). [cited by applicant]
Belfort et al., “Homing Endonucleases: From Genetic Anomalies to Programmable Genomic Clippers,” Methods in Molecular Biology, vol. 1123, pp. 1-26 (2014). [cited by applicant]
Bennardo et al., “Limiting the Persistence of a Chromosome Break Diminishes Its Mutagenic Potential,” PLoS Genetics, vol. 5, No. 10:e1000683, pp. 1-14 (Oct. 2009). [cited by applicant]
Bird et al., “Single-chain antigen-binding proteins,” Science, vol. 242, No. 4877, pp. 423-427 (1988). [cited by applicant]
Boissel et al., “megaTALS: a rare-cleaving nuclease architecture for therapeutic genome engineering,” Nucleic Acids Research, vol. 42, No. 4, pp. 2591-2601 (2014). [cited by applicant]
Brinkman et al., “Easy quantitative assessment of genome editing by sequence trace decomposition,” Nucleic Acids Research, vol. 42, No. 22, e168, pp. 1-8 (2014). [cited by applicant]
Brown et al., “A mammalian protein targeted by G1-arresting rapamycin-receptor complex,” Nature, vol. 369, No. 6483, pp. 756-758 (1994). [cited by applicant]
Brunner et al., “Cytotoxic T cells: Double-barreled shot guns,” Nature Medicine, vol. 5, No. 1, 1 page (Jan. 1999). [cited by applicant]
Certo et al., “Coupling endonucleases with DNA end-processing enzymes to drive gene disruption,” Nat. Methods, vol. 9, No. 10, pp. 973-975 (Oct. 2012). [cited by applicant]
Certo et al., “Tracking genome engineering outcome at individual DNA breakpoints,” Nat Methods, vol. 8, No. 8, pp. 671-676 (2012). [cited by applicant]
Chaudhary et al., “A rapid method of cloning functional variable-region antibody genes in [cited by applicant]
Chevalier et al., “Design, Activity, and Structure of a Highly Specific Artificial Endonuclease,” Molecular Cell, vol. 10, pp. 895-905 (Oct. 2002). [cited by applicant]
Clever et al., “RNA Secondary Structure and Binding Sites for gag Gene Products in the 5′ Packaging Signal of Human Immunodeficiency Virus Type 1,” Journal of Virology, vol. 69, No. 4, pp. 2101-2109 (1995). [cited by applicant]
Cullen et al., “Regulatory Pathways Governing HIV-1 Replication”, Cell, vol. 58, pp. 423-426 (1989). [cited by applicant]
Cullen, B.R., “Human Immunodeficiency Virus as a Prototypic Complex Retrovirus,” Journal of Virology, vol. 65, No. 3, pp. 1053-1056 (1991). [cited by applicant]
Database Geneseq [Online] Oct. 24, 2013 (Oct. 24, 2013), “I-Onul homing endonuclease, SEQ 15,” XP002798406, retrieved from EBI accession No. GSP:BAS88181 Database accession No. BAS88181 *sequence *. [cited by applicant]
Dayhoff et al., “A model of evolutionary change in proteins. In: Atlas of Protein Sequence and Structure,” M.O. Dayhoff, ed., National Biomedical Research Foundation, Washington, DC., pp. 345-358 (1978). [cited by applicant]
De Felipe et al., “Targeting of Proteins Derived from Self-Processing Polyproteins Containing Multiple Signal Sequences,” Traffic, vol. 5, No. 8, pp. 616-626 (2004). [cited by applicant]
Desjarlais et al., “Length-encoded multiplex binding site determination: application to zinc finger proteins,” Proceedings of the National Academy of Sciences, vol. 91, No. 23, pp. 11099-11103 (1994). [cited by applicant]
Desjarlais et al., “Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins,” Proceedings of the National Academy of Sciences, vol. 90, No. 6, pp. 2256-2260 (1993). [cited by applicant]
Donnelly et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” Journal of General Virology, vol. 82 (Pt 5), pp. 1027-1041 (2001). [cited by applicant]
Duan et al., “Expanding AAV Packaging Capacity with Trans-splicing or Overlapping Vectors: A Quantitative Comparison,” Molecular Therapy, vol. 4, No. 4, pp. 383-391 (2001). [cited by applicant]
Duke et al., “Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation,” Journal of Virology, vol. 66, No. 3, pp. 1602-1609 (1992). [cited by applicant]
Dull et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System,” Journal of Virology, vol. 72, No. 11, pp. 8463-8671 (1998). [cited by applicant]
Epinat et al., “A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells,” Nucleic Acids Research, vol. 31, No. 11, pp. 2952-2962 (2003). [cited by applicant]
Extended European Search Report issued Jun. 15, 2020 in EP Application No. 17849655.0. [cited by applicant]
GenBank Accession No. AAA58476.1, “FK506-binding protein 12 [ [cited by applicant]
GenBank Accession No. L34075.1, “Human FKBP-rapamycin associated protein (FRAP) mRNA, complete cds,” Dec. 31, 1994, 4 pages. [cited by applicant]
Ghosh et al., “A Hybrid Vector System Expands Adeno-associated Viral Vector Packaging Capacity in a Transgene-Independent Manner,” Molecular Therapy. vol. 16, No. 1, pp. 124-130 (2008). [cited by applicant]
Ghosh et al., “Efficient Transgene Reconstitution with Hybrid Dual AAV Vectors Carrying the Minimized Bridging Sequences,” Human Gene Therapy, vol. 22, No. 1, pp. 77-83 (2011). [cited by applicant]
Ghosh et al., “Viral serotype and the transgene sequence influence overlapping adeno- associated viral (AAV) vector-mediated gene transfer in skeletal muscle,” J. Gene Med., vol. 8, No. 3, pp. 298-305 (2006). [cited by applicant]
Gomez-Foix et al., “Adenovirus-mediated Transfer of the Muscle Glycogen Phosphorylase Gene into Hepatocytes Confers Altered Regulation of Glycogen Metabolism,” J. Biol. Chem., vol. 267, No. 35, pp. 25129-25134 (Dec. 15,… [cited by applicant]
Graham et al., “Adenovirus-Based Expression Vectors and Recombinant Vaccines,” Vaccines: New Approaches to Immunological Problems, Chapter 16, pp. 363-390 (1992). [cited by applicant]
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol., vol. 36, pp. 59-72 (1977). [cited by applicant]
Graham et al., “Manipulation of Adenovirus Vectors,” Methods in Molecular Biology, vol. 7: Gene Transfer and Expression Protocols, Chapter 11, pp. 109-129 (1991). [cited by applicant]
Grunhaus et al., “Adenoviruses as cloning vectors,” Semin. Virol., vol. 3, pp. 237-252 (1992). [cited by applicant]
Hensgens et al., “Two Intron Sequences in Yeast Mitochondrial COX1 Gene: Homology among URF-Containing Introns and Strain-Dependent Variation in Flanking Exons,” Cell, vol. 32, pp. 379-389 (Feb. 1983). [cited by applicant]
Herz et al., “Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice,” PNAS USA, vol. 90, pp. 2812-2816 (1993). [cited by applicant]
Huang et al., “Role of the Hepatitis B Virus Posttranscriptional Regulatory Element in Export of Intronless Transcripts,” Molecular and Cellular Biology, vol. 15, No. 7, pp. 3864-3869 (1995). [cited by applicant]
Huez et al., “Two Independent Internal Ribosome Entry Sites Are Involved in Translation Initiation of Vascular Endothelial Growth Factor mRNA,” Molecular and Cellular Biology, vol. 18, No. 11, pp. 6178-6190 (Nov. 1998). [cited by applicant]
International Search Report and Written Opinion issued Mar. 4, 2020 in International Application No. PCT/US2019/065223. [cited by applicant]
International Search Report and Written Opinion issued Jul. 20, 2020 in International Application No. PCT/US2019/065211. [cited by applicant]
International Search Report and Written Opinion issued Nov. 16, 2017 in International Application No. PCT/US2017/050774. [cited by applicant]
Irion et al., “Identification and targeting of the ROSA26 locus in human embryonic stem cells,” Nature Biotechnology, vol. 25, No. 12, pp. 1477-1482 (2007). [cited by applicant]
Jackson et al., “Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond,” RNA, vol. 1, No. 10, pp. 985-1000 (1995). [cited by applicant]
Jackson et al., “The novel mechanism of initiation of picornavirus RNA translation,” Trends Biochem. Sci., vol. 15, No. 12, pp. 477-483 (1990). [cited by applicant]
Jarjour et al., “High-resolution profiling of homing endonuclease binding and catalytic specificity using yeast surface display,” Nucleic Acids Research, vol. 37, No. 20, pp. 6871-6880 (2009). [cited by applicant]
Jones et al., “Isolation of Deletion and Substitution Mutants of Adenovirus Type 5,” Cell, vol. 13, pp. 181-188 (1978). [cited by applicant]
Chan et al., The Design and In Vivo Evaluation of Engineered I-OnulBased Enzymes for HEG Gene Drive, 8(9) Plos One 1-5 (Sep. 2013). [cited by applicant]
Cox et al., Therapeutic genome editing: prospects and challenges, 21(2) Nature Medicine 121-131 (2015). [cited by applicant]
Zhang et al., Research progress in engineered nucleases for genome site-specific editing, 33(12) Basic & Clinical Medicine 1634-1637 (Dec. 2013) (English abstract). [cited by applicant]
GenPept 6BD0_A, Chain A, Ribosomal protein 3/homing endonuclease-like protein fusion (available through NCBI; disclosed by Brown, C., Zhang, K., Laforet, M., McMurrough, T.A., Gloor, G.B., Edgell, D.R.and Junop, M. in 2… [cited by applicant]
Lambert et al., “Indirect DNA sequence recognition and its impact on nuclease cleavage activity,” Structure 24(6): 862-873 (Jun. 7, 2016). [cited by applicant]